Journal Based CME - Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer

Recent advances in bioengineering and manufacturing have catapulted Antibody–drug conjugates (ADCs) to broader clinical applications. ADCs take advantage of the exquisite specificity of monoclonal antibodies (mAb) to deliver a highly potent cytotoxic agent to a specifically targeted cell expressing a selected antigen. HER2-positive breast cancer has served as a testing ground for ADC development in solid tumors that over-express HER2/neu by linking trastuzumab to a payload agent. With the current advances, ADCs leverage the selective targeting of monoclonal antibodies to deliver highly potent agents which otherwise have a narrow therapeutic index.  This journal-based accredited continuing education (CME) activity focuses on the broader clinical applications of antibody-drug conjugates. 

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($0.00)

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

ACCREDITATION

1.00 AMA PRA Category 1 Credit™

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

 

Learning Objectives

Upon successful completion of this journal-based continuing education activity, participants will be able to:

  • Identify broader clinical applications of antibody-drug conjugates
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.
Course opens: 
08/24/2022
Course expires: 
08/24/2023
Cost:
$0.00

This is a journal based continuing education activity. Please read the following article in the International Journal of Cancer Care and Delivery and login to your account on this site to claim credit.  "Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer" authored by Fengting Yan, MD, Lian Sun, BS, Aimee Wu, Henry Kaplan, MD

Link to article 

FACULTY

Fenting Yang, MD - author

Lian Sun, BS - author

Aimee Wu - author

Henry Kaplan, MD - author

Binay Shah, MD, MHA - planning committee

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 1.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 1.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 1.00 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($0.00) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

CANCELLATION POLICY

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

REFUND POLICY 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued.